Azitra CEO details strategic pivot to cosmetic ingredients and recombinant proteins; pauses Netherton trial

Azitra, Inc.

Raised $10.5M in March with up to $21M additional from warrant exercises to fund new initiatives.
Launches ATR-COSF, a recombinant filaggrin cosmetic ingredient; expects clinical study completion in late 2026.
In-licenses FHCC minicircle plasmids showing 100,000x improvement; targets TEV protease and T7 RNA Polymerase market (~$1B).
ATR-04 (EGFR inhibitor rash) continues enrollment with MD Anderson as new clinical site.
Pauses ATR-12 Netherton trial enrollment to redirect capital to ATR-COSF near-term milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.